Due to the significant reduction of CV risk with empagliflozin, dapagliflozin, and canagliflozin in patients with T2DM, these benefits were once considered as class effects of SGLT2 inhibitors (135). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.